Feb 1, 2012 by Brian Orelli, PhDSide Effect of Low Side Effects: 20% Stock GainMedivation and Astellas have good news for patients and investors.
Feb 1, 2012 by Brian Orelli, PhDMaximum Market: $2.9 Billion, For NowVertex gains FDA approval for cystic fibrosis treatment Kalydeco.
Jan 31, 2012 by Brian Orelli, PhDFDA Approval Isn't EnoughSometimes it takes more than one indication to really shine.
Jan 31, 2012 by Brian Orelli, PhDLipitor Loss? What's That?Pfizer loses Lipitor exclusivity and still beats analysts.
Jan 30, 2012 by Brian Orelli, PhDHasn't Cell Therapeutics Ever Heard of All-Nighters?The biotech withdraws its application to delay a test.
Jan 30, 2012 by Brian Orelli, PhDWhich Big Biotech Is the Best Bet?That might depend on which kind of investor you are.
Jan 27, 2012 by Brian Orelli, PhD2 Biotech Acquisitions in 1 Day! Let's Throw a PartyAmgen and Celgene pull the trigger. Don't drop the keg.
Jan 26, 2012 by Brian Orelli, PhDThis Biotech is Going GlobalSpectrum Pharma staking a claim outside the U.S.
Jan 25, 2012 by Brian Orelli, PhDHang Tight: This Bid Will IncreaseRoche will probably bid higher for Illumina.
Jan 24, 2012 by Brian Orelli, PhDThe Most Important Thing for This BiotechZevalin needs to pick up the pace.
Jan 23, 2012 by Brian Orelli, PhD50% of This Market Would Be Just FineBiogen and Elan stratify Tysabri's PML risk.
Jan 20, 2012 by Brian Orelli, PhD19 Clinical Trials Aren't EnoughThe FDA rejects Bristol-Myers and AstraZeneca's dapagliflozin.
Jan 19, 2012 by Brian Orelli, PhDNew Hep C Data Impressive, but It's Not There YetAll-oral treatment still has a ways to go.
Jan 18, 2012 by Brian Orelli, PhD2 High-Flying Biotechs Face a New HurdleComparing clinical trials can be difficult.
